Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
21. Mai 2024 07:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
08. Mai 2024 07:00 ET
|
Avadel Pharmaceuticals plc
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
01. Mai 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it...
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
01. April 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
05. März 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Issues Statement On Patent Litigation
04. März 2024 15:37 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
04. März 2024 06:30 ET
|
Avadel Pharmaceuticals plc
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31st, greater than 2,200 patients enrolled in...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
26. Februar 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07. Februar 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights
08. Januar 2024 07:00 ET
|
Avadel Pharmaceuticals plc
-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively -- -- Generated continued robust demand for...